Fr. 134.00

Bortezomib in the Treatment of Multiple Myeloma

English · Hardback

Shipping usually within 2 to 3 weeks (title will be printed to order)

Description

Read more

Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways.This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.

List of contents










.

Summary

Multiple Myeloma (MM) is the second most common type of blood cancer, resulting from an overproduction of cancerous infection-fighting white blood cells, known as plasma cells. Plasma cells are a crucial part of the immune system responsible for the production of antibodies. Bortezomib is a promising anticancer drug targeting the proteasome. This proteasome inhibitor induces cell stress and apoptosis in the cancer cells. While multiple mechanisms are likely to be involved, proteasome inhibition may prevent the degradation of pro-apoptotic factors, permitting activation of programmed cell death in neoplastic cells dependent upon the suppression of proapoptotic pathways.
This monograph on bortezomib is a valuable source of information for researchers and clinicians from the fields of oncology and pharmacology, working either in academia or the pharmaceutical industry.

Product details

Assisted by Kenneth C. Anderson (Editor), Kenneth C Anderson (Editor), Pau G Richardson (Editor), Paul G Richardson (Editor), Irene M. Ghobrial (Editor), Paul G. Richardson (Editor)
Publisher Springer, Basel
 
Languages English
Product format Hardback
Released 23.11.2010
 
EAN 9783764389475
ISBN 978-3-7643-8947-5
No. of pages 180
Weight 438 g
Illustrations VIII, 180 p.
Series Milestones in Drug Therapy
Milestones in Drug Therapy
Subjects Natural sciences, medicine, IT, technology > Medicine > Clinical medicine

B, Oncology, Pharmacology, Biomedical and Life Sciences, Cancer Research, Cellular biology (cytology), Pharmacology/Toxicology, Apoptosis, Cancer Biology, Cell Death

Customer reviews

No reviews have been written for this item yet. Write the first review and be helpful to other users when they decide on a purchase.

Write a review

Thumbs up or thumbs down? Write your own review.

For messages to CeDe.ch please use the contact form.

The input fields marked * are obligatory

By submitting this form you agree to our data privacy statement.